

*Description of Respondents:* Coal mining operators and State regulatory authorities.

*Total Annual Responses:* 186,341.  
*Total Annual Burden Hours:* 870,333.

Dated: October 1, 2003.

**Richard G. Bryson,**

*Chief, Division of Regulatory Support.*

[FR Doc. 03-25299 Filed 10-6-03; 8:45 am]

**BILLING CODE 4310-05-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application**

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 1, 2003, Cayman Chemical Company, 1180 East Ellsworth Road, Ann Arbor, Michigan 48108, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Marihuana (7360) .....	I
Tetrahydrocannabinols (7370) .....	I

The firm plans to manufacture small quantities of marijuana derivatives for research purpose.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration. Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than December 8, 2003.

Dated: September 17, 2003.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control.*

[FR Doc. 03-25310 Filed 10-6-03; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Registration**

By Notice dated June 6, 2003, and published in the **Federal Register** on

June 19, 2003, (68 FR 26841), AccusStandard Inc., 125 Market Street, New Haven, Connecticut 06513, made application by renewal and on May 7, 2003, by letter to the Drug Enforcement Administration to be registered as a bulk manufacturer of the basic classes of Schedule I and II controlled substances listed below:

Drug	Schedule
Cathinone (1235) .....	I
Methcathinone (1237) .....	I
N-Ethylamphetamine (1475) .....	I
N,N-Dimethylamphetamine (1480) .....	I
Fenethylamine (1503) .....	I
Aminorex (1585) .....	I
4-Methylaminorex (cis isomer) (1590) .....	I
Gamma hydroxybutyric acid (2010) .....	I
Methaqualone (2565) .....	I
Mecloqualone (2372) .....	I
Alpha-Ethyltryptamine (7249) .....	I
Ibogaine (7260) .....	I
Lysergic acid diethylamide (7315) .....	I
Tetrahydrocannabinols (7370) .....	I
Mescaline (7381) .....	I
3,4,5-Trimethoxyamphetamine (7390) .....	I
4-Bromo-2,5-dimethoxyamphetamine (7391) .....	I
4-Bromo-2,5-dimethoxyphenethylamine (7392) .....	I
4-methyl-2,5-dimethoxyamphetamine (7395) .....	I
2,5-Dimethoxymphetamine (7396) .....	I
2,5-Dimethoxy-4-ethylamphetamine (7399) .....	I
3,5-Methylenedioxyamphetamine (7400) .....	I
5-Methoxy-3,4-methylenedioxyamphetamine (7401) .....	I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402) .....	I
3,4-Methylenedioxy-N-ethylamphetamine (7404) .....	I
3,4-Methylenedioxy-N-methylamphetamine (7405) .....	I
4-Methoxyamphetamine (7411) .....	I
Befotenine (7433) .....	I
Diethyltryptamine (7434) .....	I
Dimethyltryptamine (7435) .....	I
Psilocybin (7437) .....	I
Psilocyn (7438) .....	I
N-Ethyl-1-phenylcyclohexylamine (7455) .....	I
1-(1-Phenylcyclohexyl) pyrrolidine (PCPY) (7458) .....	I
Noracymethadol (9633) .....	I
Norlevorphanol (9634) .....	I
Normethadone (9635) .....	I
Norpipanone (9636) .....	I
Phenadoxone (9637) .....	I
Phenampromide (9638) .....	I
Phenoperidine (9641) .....	I
Piritramide (9642) .....	I
Propeptazine (9643) .....	I
Properidine (9644) .....	I
Racemoramide (9645) .....	I

Drug	Schedule
Trimeperidine (9646) .....	I
Phenomorphan (9647) .....	I
Propiram (9649) .....	I
1-Methyl-4-phenyl-4-propionoxypiperidine (9661) .....	I
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine (9663) .....	I
Tilidine (9750) .....	I
Para-Fluorofentanyl (9812) .....	I
3-Methylfentanyl (9813) .....	I
Alpha-Methylfentanyl (9814) .....	I
Acetyl-alpha-methylfentanyl (9815) .....	I
Benzylfentanyl (9818) .....	I
Beta-Hydroxyfentanyl (9830) .....	I
Beta-Hydroxy-3-methylfentanyl (9831) .....	I
Alpha-Methylthiofentanyl (9832) .....	I
3-Methylthiofentanyl (9833) .....	I
Thenylfentanyl (9834) .....	I
Thiofentanyl (9835) .....	I
Amphetamine (1100) .....	II
Methamphetamine (1105) .....	II
Phenmetrazine (1631) .....	II
Methylphenidate (1724) .....	II
Amobarbital (2125) .....	II
Pentobarbital (2270) .....	II
Secobarbital (2315) .....	II
Glutethimide (2250) .....	II
Nabilone (7379) .....	II
1-Phenylcyclohexylamine (7460) .....	II
Phencyclidine (7471) .....	II
Phenylacetone (8501) .....	II
1-Piperidinocyclohexane-carbonitrile (8603) .....	II
Alphaprodine (9010) .....	II
Anileridine (9020) .....	II
Cocaine (9041) .....	II
Codeine (9050) .....	II
Diprenorphine (9058) .....	II
Etorphine HCL (9059) .....	II
Dihydrocodeine (9120) .....	II
Oxycodone (9143) .....	II
Hydromorphone (9150) .....	II
Diphenoxylate (9170) .....	II
Benzoylcegonine (9180) .....	II
Ecgonine (9180) .....	II
Ethylmorphine (9190) .....	II
Hydrocodone (9193) .....	II
Levomethorphan (9210) .....	II
Levorphanol (9220) .....	II
Isomethadone (9226) .....	II
Meperidine (9230) .....	II
Meperidine intermediate-A (9232) .....	II
Meperidine intermediate-B (9233) .....	II
Meperidine intermediate-C (9234) .....	II
Metazocine (9240) .....	II
Methadone (9250) .....	II
Methadone intermediate (9254) .....	II
Metopon (9260) .....	II
Morphine (9300) .....	II
Thebaine (9333) .....	II
Dihydroetorphine (9334) .....	II
Opium, raw (9600) .....	II
Opium tincture (9630) .....	II
Opium powered (9639) .....	II
Levo-alphaacetylmethadol (9648) .....	II
Oxymorphone (9652) .....	II
Phenazocine (9715) .....	II
Piminodine (9730) .....	II
Racemethorphan (9732) .....	II
Racemorphan (9733) .....	II
Alfentanil (9737) .....	II
Remifentanil (9739) .....	II

Drug	Schedule
Sufentanil (9740) .....	II
Carfentanil (9743) .....	II
Bezitramide (9800) .....	II
Fentanyl (9801) .....	II
Moramide-intermediate (9802) .....	II

The firm plans to manufacture small quantities of bulk material for use in reference standards.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of AccuStandard Inc. to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated AccuStandard Inc. to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed is granted.

Dated: September 17, 2003.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 03-25308 Filed 10-6-03; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled substances; Notice of Registration**

By Notice dated June 6, 2003, and published in the **Federal Register** on June 19, 2003, (68 FR 36843), CellTech Manufacturing CA., Inc., 3501 West Garry Avenue, Santa Ana, California 92704, made application by renewal to the Drug Enforcement Administration to be registered as a bulk manufacturer of Methylphenidate (1724), a basic class of controlled substance listed in Schedule II.

The firm plans to manufacture the controlled substance to make finished dosage forms for distribution to its customers.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code,

section 823(a) and determined that the registration of CellTech Manufacturing CA. Inc. to manufacture the listed controlled substance is consistent with the public interest at this time. DEA has investigated CellTech Manufacturing CA., Inc. to ensure that the company's registration is consistent with the public interest.

This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed is granted.

Dated: September 17, 2003

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 03-25408 Filed 10-6-03; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled substances; Notice of Application**

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 19, 2003, National Center for Natural Products Research—NIDA MProject, University of Mississippi, 135 Coy Waller Complex, University, Mississippi 38677, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Marihuana (7360) .....	I
Tetrahydrocannabinols (7370) .....	I

The firm plans to cultivate marijuana for the National Institute of Drug Abuse for research approved by the Department of Health and Human Services.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator,

Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than December 8, 2003.

Dated: September 17, 2003.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control.*

[FR Doc. 03-25309 Filed 10-6-03; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled substances; Notice of Registration**

By Notice dated May 16, 2003, and published in the **Federal Register** on June 11, 2003, (68 FR 35006), Noramco, Inc. (formerly Noramco of Delaware, Inc.), 500 Swedes Landing Road, Wilmington, Delaware 19801, made application by renewal and on December 4 and 26, 2002, by letters to the Drug Enforcement Administration to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Codeine-N-Oxide (9053) .....	I
Morphine-N-Oxide (9307) .....	I
Codeine (9050) .....	II
Oxycodone (9143) .....	II
Hydrocodone (9193) .....	II
Morphine (9300) .....	II
Thebaine (9333) .....	II
Oxymorphone (9652) .....	II

The firm plans to manufacture the listed controlled substances for distribution to its customers as bulk products.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the registration of Noramco, Inc. to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Noramco, Inc. to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy